inclusion criteria: * patients ≥ 18 years * patients with documented recent covid19 infection (\>4 weeks) * pasc syndrome, defined by persistence or new symptoms, not present prior to the infection. * cmr evidence of inflammatory cardiac involvement at bl by any of the following criteria: * increased native t1≥ 1130 ms at 3.0 tesla (or 1030 ms at 1.5 tesla) and/or; * increased native t2 ≥39.5 ms at 3.0 tesla (or 49.5 at 1.5 tesla) and/or * present non-ischaemic myopericardial lge and/or; * lvef ≥45 - ≤50%. * willingness to comply with the study procedures and study protocol

inclusion criteria: * patients ≥ 18 years * patients with documented recent covid19 infection (\>4 weeks) * pasc syndrome, defined by persistence or new symptoms, not present prior to the infection. * cmr evidence of inflammatory cardiac involvement at bl by any of the following criteria: * increased native t1≥ 1130 ms at 3.0 tesla (or 1030 ms at 1.5 tesla) and/or; * increased native t2 ≥39.5 ms at 3.0 tesla (or 49.5 at 1.5 tesla) and/or * present non-ischaemic myopericardial lge and/or; * lvef ≥45 - ≤50%. * willingness to comply with the study procedures and study protocol

inclusion criteria: patients ≥ 18 years patients with documented recent covid19 infection (>4 weeks) pasc syndrome, defined by persistence or new symptoms, not present prior to the infection. cmr evidence of inflammatory cardiac involvement at bl by any of the following criteria: increased native t1≥ 1130 ms at 3.0 tesla (or 1030 ms at 1.5 tesla) and/or; increased native t2 ≥39.5 ms at 3.0 tesla (or 49.5 at 1.5 tesla) and/or present non-ischaemic myopericardial lge and/or; lvef ≥45 - ≤50%. willingness to comply with the study procedures and study protocol

inclusion criteria: patients ≥ 18 years patients with documented recent covid19 infection (>4 weeks) pasc syndrome, defined by persistence or new symptoms, not present prior to the infection. cmr evidence of inflammatory cardiac involvement at bl by any of the following criteria: increased native t1≥ 1130 ms at 3.0 tesla (or 1030 ms at 1.5 tesla) and/or; increased native t2 ≥39.5 ms at 3.0 tesla (or 49.5 at 1.5 tesla) and/or present non-ischaemic myopericardial lge and/or; lvef ≥45 - ≤50%. willingness to comply with the study procedures and study protocol

inclusion criteria: patients ≥ 18 years patients with documented recent covid19 infection (>4 weeks and <6 months) pasc syndrome, defined by persistence or new symptoms, not present prior to the infection. cmr evidence of inflammatory cardiac involvement at bl by any of the following criteria: increased native t1≥ 1130 ms at 3.0 tesla (or 1030 ms at 1.5 tesla) and/or; increased native t2 ≥39.5 ms at 3.0 tesla (or 49.5 at 1.5 tesla) and/or present non-ischaemic myopericardial lge and/or; lvef ≥45 - ≤50%. willingness to comply with the study procedures and study protocol

inclusion criteria: patients ≥ 18 years patients with documented recent covid19 infection (>4 weeks and <6 months) pasc syndrome, defined by persistence or new symptoms, not present prior to the infection. cmr evidence of inflammatory cardiac involvement at bl by any of the following criteria: increased native t1≥ 1130 ms at 3.0 tesla (or 1030 ms at 1.5 tesla) and/or; increased native t2 ≥39.5 ms at 3.0 tesla (or 49.5 at 1.5 tesla) and/or present non-ischaemic myopericardial lge and/or; lvef ≥45 - ≤50%. willingness to comply with the study procedures and study protocol